Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
← catalyst calendarNCT06158841 · readout ≤ 499 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
380estimated
Sites
166
Countries
Australia, Austria, Belgium +22
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-19 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-12-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Interventions
- Drug: Etentamig — also filed as ABBV-383
- Drug: Carfilzomib
- Drug: Pomalidomide
- Drug: Elotuzumab
- Drug: Selinexor
- Drug: Bortezomib
- Drug: Dexamethasone
Primary outcomes
what the primary-completion date above is the date OFProgression Free Survival (PFS)
measured Up to Approximately 5 Years
Objective Response Rate (ORR)
measured Up to Approximately 5 Years
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed